Savlon Antiseptic Cream Cetrimide 0.5% w/wChlorhexidine Digluconate 0.1% w/w

Land: Irland

Språk: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Aktiv ingrediens:

Cetrimide; Chlorhexidine gluconate

Tilgjengelig fra:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

ATC-kode:

D08AJ; D08AJ04

INN (International Name):

Cetrimide; Chlorhexidine gluconate

Dosering :

0.5/0.1 percent weight/weight

Legemiddelform:

Cream

Resept typen:

Product not subject to medical prescription

Terapeutisk område:

Quaternary ammonium compounds; cetrimide

Autorisasjon status:

Marketed

Autorisasjon dato:

1991-06-26

Preparatomtale

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Savlon Antiseptic Cream
Cetrimide 0.5% w/w
Chlorhexidine Digluconate 0.1% w/w
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredients:
Cetrimide 0.50% w/w
Chlorhexidine digluconate 0.10% w/w
Excipients:
Cetostearyl alcohol 10.00% w/w
Methyl parahydroxybenzoate (E218) 0.01% w/w
Propyl parahydroxybenzoate (E216) 0.01% w/w
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Cream.
Smooth, white, homogenous cream with an antiseptic odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For prevention and management of superficial infections in skin tissue
including wounds and minor burns.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For cutaneous use.
Apply the cream over the affected area after cleansing.
4.3 CONTRAINDICATIONS
Hypersensitivity to chlorhexidine digluconate, cetrimide or to any of
the excipient listed in section 6.1
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
For external use only.
Avoid contact with the eyes, ears, mouth or other mucosa.
If accidentally splashed into the eye, the open eye should be
irrigated for at least 10 minutes.
If symptoms persist or condition worsens, discontinue use and consult
a physician.
The product is incompatible with anionic substances (e.g. soap).
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_3_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_8_
_C_
_R_
_N_
_ _
_2_
_2_
_0_
_5_
_9_
_8_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
Information concern